logo

Alkermes Plc (ALKS)



Trade ALKS now with
  Date
  Headline
1/17/2023 7:02:51 AM Alkermes Awarded Innovation Passport Designation By UK's MHRA For Nemvaleukin Alfa For Mucosal Melanoma Treatment
11/2/2022 7:03:50 AM Alkermes Q3 GAAP Loss Per Share $0.39 And Non-GAAP EPS $0.02; Announces Intent To Separate Oncology Business
7/27/2022 7:26:11 AM Alkermes plc (ALKS) Has Raised Its FY22 Revenue Estimate To $1,050 – $1,120 Mln From $1,000 – $1,090 Mln
7/27/2022 7:25:47 AM Alkermes plc (ALKS) Has Raised Its FY22 EPS Estimate To 0.09 - 0.27 From -0.18 - 0.00
7/27/2022 7:24:52 AM Alkermes plc Q2 Earnings Summary
7/27/2022 7:04:58 AM Alkermes Q2 GAAP Loss Per Share $0.18 And Non-GAAP EPS $0.06
7/6/2022 7:08:27 AM Sarissa Capital Comments On Alkermes Annual Meeting; Supports New Alkermes Directors To Step Up
6/1/2022 7:01:40 AM Alkermes Presents ARTISTRY-1 Data At 2022 ASCO Annual Meeting
5/27/2022 10:04:06 AM Sarissa Capital Management Shocked By Alkermes' Sudden Announcement Of Its Slate Of Director Nominees
4/27/2022 7:03:37 AM Alkermes Plc Q1 GAAP Loss Per Share $0.22; Non-GAAP EPS $0.12
2/17/2022 7:03:34 AM Alkermes Presents New Data From Ongoing Phase 1/2 ARTISTRY-1 Trial For Nemvaleukin Alfa